<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="515">
  <stage>Registered</stage>
  <submitdate>27/12/2004</submitdate>
  <approvaldate>27/12/2004</approvaldate>
  <nctid>NCT00100269</nctid>
  <trial_identification>
    <studytitle>Menevit Study: Menevit Anti-Oxidant Therapy for the Treatment of Male Infertility</studytitle>
    <scientifictitle>A Randomized Control Trial of the Menevit Anti-Oxidant Therapy for the Treatment of Male Infertility</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>RCHDW002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Infertility, Male</healthcondition>
    <healthcondition>Oxidative Stress</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Fertility including in vitro fertilisation</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Menevit anti-oxidant

Treatment: drugs: Menevit anti-oxidant


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Embryo quality (morphology score, progression to blastocyst rates, number of embryos available for freezing/transfer per cycle)</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Embryo quality is a good measure of pregnancy potential and is also an indicator of sperm DNA integrity, making it the ideal primary endpoint.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>sperm DNA fragmentation</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>sperm count</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>sperm motility (total motile sperm per ejaculate)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>sperm morphology</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>sperm membrane integrity (as assessed by hypo-osmolar swelling test)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>levels of sperm lipid peroxidation (LPO-586 assay)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>retrospective comparison of embryo quality between the Menevit IVF cycle and the preceding non-Menevit IVF cycle.</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>miscarriage rate (clinical and biochemical)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>clinical pregnancy rates (number of fetal hearts seen on first trimester scan)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>adverse side effects</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Evidence of oxidative stress to sperm on LPO-586 assay or poor HOST result or clinical
             evidence for oxidative stress (heavy smoker, varicocele, poor motility in the abscence
             of anti-sperm antibodies etc)

          -  Evidence of significant sperm DNA damage (25% or more DNA fragmentation as assessed by
             Tunel assay).

          -  Female partner willing to undergo IVF treatment within 3 months of starting Menevit
             trial</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Female partner 40 years of age or older at trial entry.

          -  Significantly reduced ovarian reserve in female partner (day 3-5 FSH &gt; 10 iu/L if no
             prior IVF cycle or less than 5 oocytes on a prior IVF cycle.

          -  Sperm count below 0.5 million per ml (impossible to conduct all sperm function assays</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Repromed - Adelaide</hospital>
    <postcode>5065 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Repromed</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Oxidative stress related damage to sperm is believed to be a major cause of male infertility.
      The object of the Menevit study is to investigate the role of a novel anti-oxidant
      preparation (Menevit) on sperm function, embryo quality and pregnancy rates in an in vitro
      fertilization (IVF) setting.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00100269</trialwebsite>
    <publication>Aitken RJ, Baker MA. Oxidative stress and male reproductive biology. Reprod Fertil Dev. 2004;16(5):581-8. Review.
Aitken RJ, Gordon E, Harkiss D, Twigg JP, Milne P, Jennings Z, Irvine DS. Relative impact of oxidative stress on the functional competence and genomic integrity of human spermatozoa. Biol Reprod. 1998 Nov;59(5):1037-46.
Benchaib M, Braun V, Lornage J, Hadj S, Salle B, Lejeune H, Gu√©rin JF. Sperm DNA fragmentation decreases the pregnancy rate in an assisted reproductive technique. Hum Reprod. 2003 May;18(5):1023-8.
Henkel R, Hajimohammad M, Stalf T, Hoogendijk C, Mehnert C, Menkveld R, Gips H, Schill WB, Kruger TF. Influence of deoxyribonucleic acid damage on fertilization and pregnancy. Fertil Steril. 2004 Apr;81(4):965-72.
Carrell DT, Liu L, Peterson CM, Jones KP, Hatasaka HH, Erickson L, Campbell B. Sperm DNA fragmentation is increased in couples with unexplained recurrent pregnancy loss. Arch Androl. 2003 Jan-Feb;49(1):49-55.
Agarwal A, Nallella KP, Allamaneni SS, Said TM. Role of antioxidants in treatment of male infertility: an overview of the literature. Reprod Biomed Online. 2004 Jun;8(6):616-27. Review.
Gomez E, Irvine DS, Aitken RJ. Evaluation of a spectrophotometric assay for the measurement of malondialdehyde and 4-hydroxyalkenals in human spermatozoa: relationships with semen quality and sperm function. Int J Androl. 1998 Apr;21(2):81-94.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Kelton P Tremellen, MB BS (Hons) PhD</name>
      <address>Repromed, University of Adelaide</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>